Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Publication year range
1.
Anticancer Drugs ; 27(1): 54-9, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26398932

ABSTRACT

To investigate the initial symptoms, treatment, prognosis, and 1-, 3-, and 5-year survival of patients with bronchopulmonary carcinoid, clinical and pathological data were collected retrospectively from 74 patients diagnosed with bronchopulmonary neuroendocrine tumors at the Cancer Hospital, Chinese Academy of Medical Science, from January 2004 through December 2009. The data collected included age, initial symptoms, primary tumor sites, pathological types, lymphatic metastasis, and distant metastasis. The Kaplan-Meier method was used for survival analysis and the log-rank test was used for univariate analysis of prognostic factors. A Cox proportional hazard regression model was used for multivariate analysis. The 74 patients included 56 men and 19 women, and their average age was 56.07 years. The most common initial symptom was cough (51.35%), and the major lesion site was the left upper lobe of the lung (38.84%). Of the 59 patients (79.73%) who underwent surgery, most (76.27%) received a pulmonary lobectomy. The patients' 1-, 3-, and 5-year survival rates were 92.7, 80.3, and 71.9%, respectively. Univariate analysis showed that both local lymphatic and distant metastases were prognostic factors (P<0.05), whereas multivariate analysis showed that the pathological type (typical carcinoid and atypical carcinoid) was an independent prognostic factor (P=0.006). These data indicate that cough is the major presenting symptom of patients with bronchopulmonary carcinoid and the left upper lobe of the lung is the most commonly involved site. Following treatment, mostly by pulmonary lobectomy, the 5-year survival rate is 71.9%. The pathological tumor type is an independent prognostic factor.


Subject(s)
Bronchial Neoplasms/diagnosis , Bronchial Neoplasms/therapy , Carcinoid Tumor/diagnosis , Carcinoid Tumor/therapy , Lung Neoplasms/diagnosis , Lung Neoplasms/therapy , Adult , Aged , Carcinoid Tumor/surgery , Chemotherapy, Adjuvant , Combined Modality Therapy , Female , Humans , Male , Middle Aged , Neoplasm Metastasis , Neoplasm Recurrence, Local , Prognosis , Retrospective Studies , Survival Analysis , Young Adult
2.
Zhonghua Zhong Liu Za Zhi ; 35(1): 67-70, 2013 Jan.
Article in Chinese | MEDLINE | ID: mdl-23648305

ABSTRACT

OBJECTIVE: To investigate the epidemiology, diagnosis, and treatment status of neuroendocrine tumors (NETs) in our hospital. METHODS: Medical records of 252 patients with neuroendocrine tumors diagnosed and treated in our hospital from January 1, 2004 to December 31, 2009 were collected and retrospectively reviewed in this study. The clinicopathological data including age of onset, initial symptoms, primary site, pathological conditions (Sny, CgA, Ki-67), disease stage at diagnosis, treatment, and follow up were analyzed. RESULTS: The gender ratio M/F of the 252 cases was 1.9:1, with mean age of 55.2 years, and the high incidence was in age of 60-69 years. The tumors were located in the gastrointestinal tract (117 cases, 46.4%), broncho-pulmonary system (74 cases, 29.4%), other sites (61 cases, 24.2%) and unknown primary site (2 cases, 0.8%). Their first clinical symptoms vary, depending on the primary site. The common symptoms of primary rectal NETs were changes in bowel habits (29.3%) and diarrhea or constipation (17.5%), and most gastric NETs presented epigastric discomfort (86.4%). Most patients (71.4%) were diagnosed with stage I, II, III disease. Among the 252 cases, there were 110 carcinoids (43.7%), 108 neuroendocrine carcinomas (42.9%), 23 atypical carcinoids (9.1%), five neuroendocrine tumors (2.0%), four Merkel cell tumors (1.6%), and two composite carcinoids (0.8%). 206 patients (81.7%) received surgery, 39 (15.5%) received chemotherapy, and 31 cases (12.3%) were treated by palliative radiotherapy. CONCLUSIONS: This single-center retrospective analysis of data demonstrated that males have a higher incidence rate than females. The most common primary sites of NETs are the digestive tract and lungs. The initial symptoms of NETs are different depending on their primary sites. Good prognosis can be achieved in the majority of patients after surgery, chemotherapy and palliative radiotherapy.


Subject(s)
Digestive System Neoplasms/pathology , Lung Neoplasms/pathology , Neuroendocrine Tumors/pathology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carboplatin/administration & dosage , Carcinoid Tumor/drug therapy , Carcinoid Tumor/pathology , Carcinoid Tumor/radiotherapy , Carcinoid Tumor/surgery , Carcinoma, Merkel Cell/drug therapy , Carcinoma, Merkel Cell/pathology , Carcinoma, Merkel Cell/radiotherapy , Carcinoma, Merkel Cell/surgery , Carcinoma, Neuroendocrine/drug therapy , Carcinoma, Neuroendocrine/pathology , Carcinoma, Neuroendocrine/radiotherapy , Carcinoma, Neuroendocrine/surgery , Cisplatin/administration & dosage , Digestive System Neoplasms/drug therapy , Digestive System Neoplasms/radiotherapy , Digestive System Neoplasms/surgery , Etoposide/administration & dosage , Female , Fluorouracil/administration & dosage , Follow-Up Studies , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/radiotherapy , Lung Neoplasms/surgery , Male , Middle Aged , Neoplasm Staging , Neuroendocrine Tumors/drug therapy , Neuroendocrine Tumors/radiotherapy , Neuroendocrine Tumors/surgery , Organoplatinum Compounds/administration & dosage , Oxaliplatin , Paclitaxel/administration & dosage , Palliative Care , Retrospective Studies , Sex Factors , Survival Rate , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL